| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Sports Medicine (M.L., R.L., P.N.), Department of Surgical and Perioperative Sciences, Department of Geriatric Medicine (P.N.), and Department of Musculosceletal Research (R.L.), National Institute for Working Life, Umeå University, 901 85 Umeå, Sweden
Address correspondence and requests for reprints to: Mattias Lorentzon, M.Sc., Sports Medicine, Department of Surgical and Perioperative Sciences, Umeå University, 901 85 Umeå, Sweden.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Because vitamin D is likely to regulate growth via effects on bone size, we hypothesized that any association of VDR polymorphism and growth in our population would be observed most clearly by investigating bone size in relation to VDR genotypes. In the present study, we have investigated whether VDR polymorphism is associated with birth height, and with parameters of body growth and size, such as height, weight, and bone size, as well as BMD, during and after puberty, in a group of 90 healthy Caucasian boys.
| Subjects and Methods |
|---|
|
|
|---|
From advertisement and information in schools and local sports clubs, 96 healthy Caucasian boys participated in a longitudinal study investigating the influence of puberty on bone density at our Department. Of these boys, 92 could be reached and were asked to participate in the present study, and 91 boys volunteered. One of these boys was excluded because it was judged that he had not passed the pubertal growth spurt, leaving 90 boys [age, 16.9 ± 0.3 yr (mean ± SD)] for the present study. None of the subjects had any disease or medication known to affect bone metabolism. Weight and height were measured using standardized equipment. The subjects were divided into different pubertal stages, according to Tanner (15), by the same physician. All participants were judged to have passed the pubertal growth spurt period and were at least Tanner stage 4, based on at least two measurements of weight and height during 1 yr. Sixty-seven boys were judged to have passed puberty (Tanner 5), whereas the remaining 23 boys had not (Tanner 4). Approximately 2 yr later, a follow-up was conducted, and 88 boys were reached and could participate. At that time, the mean age of the 88 boys was 19.3 ± 0.7 yr (mean ± SD), and all boys had passed puberty and attained their approximate peak bone mass (16, 17). The 2 subjects not participating in the follow-up were both heterozygous for BsmI and TaqI and were not different in physical characteristics, bone area, or BMD, at age 17, than the other subjects in the heterozygote group. Using a questionnaire, the average amount of weight bearing physical activity per week was assessed during the last year. Parents of 60 of the subjects were measured for height, and the height of the parents of 13 subjects was obtained through interviews. All data concerning height and weight of the 90 boys studied at birth were collected through interviews with the parents. Informed written consent was given by all the participants, and the study protocol was approved by the Ethical Committee of the Medical Faculty, Umeå University.
Techniques for estimating bone density and body constitution parameters
BMD (g/cm2) of the total body, femoral neck, and lumbar spine was measured using a DPX-L dual-energy x-ray absorptiometer (Lunar Corp., Madison, WI), software version 1.3y. The bone area of the total body, humerus, and femur was measured using the same equipment and the region-of-interest option. The precision of this method has previously been discussed in detail by others (18, 19). The CV-value (SD/mean) for repeated measurements is 0.72.0% in our laboratory, depending on application (20). All analyses were made by the same investigator.
Genomic DNA analysis
Genomic DNA from the 90 boys was isolated from EDTA-stabilized blood, using the Wizard Genomic DNA Purification Kit (Promega Corp., Madison, WI). Determination of the VDR restriction fragment length polymorphisms (RFLPs) was performed as previously described, with some modifications (1, 21).
Genomic DNA (30 ng) was amplified in a 50-µL reaction mixture, consisting of 0.4 µmol/L forward primer, 0.4 µmol/L reverse primer, and 0.2 mmol/L each of dATP, dCTP, dGTP, dTTP, 1x PCR buffer, and 2.5 U Taq polymerase (Roche Molecular Biochemicals, Stockholm, Sweden).
The 825-bp region, in the intron separating exon VIII and IX, containing the polymorphic BsmI site, was amplified using primers 5'-CAACCAAGACTCAAGTACCGCGTCAGTGA-3' and 5'-AACCAGCGGAAGAGGTCAAGGG-3' in 35 cycles of 30 sec denaturation at 94 C, 30 sec annealing at 60 C, and 30 sec elongation at 72 C (Peltier Thermocycler; MJ Research, Inc., Watertown, MA).
The 740-bp region, in the intron separating exon VIII and IX and a part of exon IX, spanning the TaqI polymorphic site, was amplified with primers 5'-CAGAGCATGGACAG-GGAGCAAG-3' and 5'-GCAACTCCTCATGGCTGAGGTCTCA-3' in 35 cycles of 30 sec denaturation at 94 C, 30 sec annealing at 67 C, and 30 sec elongation at 72 C.
To assure the validity of the PCR amplifications, random samples of each polymorphic region were sequenced (Big Dye sequencing chemistry and ABI 377; Perkin-Elmer Corp., Stockholm, Sweden), and no discrepancies were found, compared with expected sequences.
The amplified products were cleaved with BsmI, and TaqI, overnight, according to the manufacturers recommendations (Roche Molecular Biochemicals), and electrophoresed and analyzed on ethidium bromide-stained agarose gel. The RFLPs were coded Bb and Tt, for BsmI and Taq, respectively, where capital letters represent absence and small letters represent presence of restriction fragment sites. To validate the accuracy of the RFLP determination, 8 random patients (of the total 90 patients) were redetermined for all polymorphic sites described above. No discrepancies were found.
Statistical analysis
Differences in physical characteristics, bone density, and bone area between the three groups defined by the VDR genotypes were then investigated using an ANOVA, with Bonferronis correction for multiple comparisons. A multiple regression analysis was used to estimate the variation in the boys adult height explained by birth height, birth weight, the parents mean height, and the VDR genotypes. The VDR genotypes were included as absence (BB) or presence (Bb, bb) of restriction site. The package for PC (SPSS, Inc., Chicago, IL) was used for the statistical analysis. A P-value less than 0.05 was considered significant.
| Results |
|---|
|
|
|---|
The BsmI allelic variants were significantly related to
birth height and weight increase from birth to age 16.9 ± 0.3 yr
(mean ± SD; Table 1
).
At birth, boys with the BB genotype were shorter than boys with Bb and
bb genotypes (P = 0.01). Boys with the BB genotype
showed less height and weight gain, from birth to age 16.9 ± 0.3
yr (mean ± SD), than their Bb and bb
counterparts (P < 0.05; Table 1
).
|
|
|
| Discussion |
|---|
|
|
|---|
A plethora of evidence indicates that vitamin D affects body growth. Vitamin D status is believed to affect intrauterine and postnatal growth (14). Further, vitamin D deficiency, either resulting from insufficient vitamin D dietary intake and deprivation of sunlight exposure or from hereditary defects in the synthesis of 1,25-dihydroxyvitamin D, is associated with growth failure (12, 13). Vitamin D metabolites are crucial in the normal differentiation of chondrocytes in the growth plate (24, 25), and injection of active vitamin D metabolites into the reserve zone of rachitic cartilage promotes endochondral bone formation, because of differentiation of cartilage cells (26, 27). Experimental studies in mice with targeted ablation of the VDR show development of hyperparathyroidism in response to hypocalcemia, and these mice fail to grow as rapidly as their VDR-sufficient littermates, weighing 10% less and having approximately 15% shorter tibias and femurs after 91 days of age (28). A diet known to prevent hyperparathyroidism in vitamin D-deficient rats was able to normalize growth in these animals (29), suggesting that hypocalcemia is the predominate cause of the inhibited skeletal growth, apart from the direct actions of vitamin D metabolites on bone. Recent data show that VDR polymorphism, defined by BsmI and Fok1 (30, 31), is associated with intestinal calcium absorption in children and in women, and BsmI alleles have been associated with renal absorption of inorganic phosphate in men (32). If these findings are of physiological importance, they could explain the difference in growth and stature seen in our population.
It has been suggested that the association between VDR gene polymorphism and BMD is influenced by differences in body size (8) or is attributable to variations in bone area (33), among the VDR allelic variants. In the present study, bone area of the total body, humerus, and femur was highly significantly associated with the VDR allelic variants, defined by BsmI, both during late puberty (17-yr-old boys) and after accretion of their approximate peak bone mass (19-yr-old boys) (16, 17), whereas no association with BMD was found.
VDR gene polymorphism has previously been associated with parameters of body size in both female and male infants (6, 7) and adults, but many of these findings are limited by inadequate sample size and homogeny and are not conclusive (8, 9, 33, 34). In 10-month-old boys, the BB genotype was associated with lower body surface area and weight, but not with length, compared with bb boys (6). To our knowledge, there are no previous studies investigating the BsmI alleles and association with growth from infancy to adulthood. In our homogenous population, though limited in size, the BB boys had lower height at birth, less growth up to late puberty (at age 17), and shorter adult stature (at age 19) than their bb counterparts.
It is not known whether the VDR polymorphisms cause functional differences of the VDR, or whether the polymorphisms are merely markers of variations in other genes, causing the phenotypic differences observed in association studies such as the present study. The BsmI polymorphism is located in an intron and the TaqI polymorphism in an exon of the VDR. The TaqI polymorphism does not cause any amino acid change in the VDR protein (35). Intronic sequences have been shown to be able to alter transcriptional activity (36), resulting in varying messenger RNA levels. It has been reported that there are no differences, with respect to BsmI allelic variants, in levels of VDR expression in either the intestine (37) or in peripheral blood mononuclear cells (38). As of now, no data is available on possible association of the VDR polymorphisms with VDR expression levels in other tissues or cells known to contain VDR, such as the kidney, osteoblasts, or chondrocytes (12).
In conclusion, we show here that VDR gene polymorphism is associated with height at birth, with adult stature, and with bone size both during and after puberty in healthy Caucasian males, implying a significant role of VDR polymorphism in skeletal growth and introducing a new parameter in the prediction model for adult stature.
| Erratum |
|---|
|
|
|---|
|
|
|
|
|
| Acknowledgments |
|---|
| Footnotes |
|---|
Received August 25, 1999.
Revised January 13, 2000.
Accepted January 12, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. B. Dunger, C. J. Petry, and K. K. Ong Genetics of Size at Birth Diabetes Care, July 1, 2007; 30(Supplement_2): S150 - S155. [Full Text] [PDF] |
||||
![]() |
Y. Fang, J. B. J. van Meurs, F. Rivadeneira, N. M. van Schoor, J. P. T. van Leeuwen, P. Lips, H. A. P. Pols, and A. G. Uitterlinden Vitamin D Receptor Gene Haplotype Is Associated with Body Height and Bone Size J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1491 - 1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Z. Stolzenberg-Solomon, R. Vieth, A. Azad, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes A Prospective Nested Case-Control Study of Vitamin D Status and Pancreatic Cancer Risk in Male Smokers Cancer Res., October 15, 2006; 66(20): 10213 - 10219. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dempfle, S. A. Wudy, K. Saar, S. Hagemann, S. Friedel, A. Scherag, L. D. Berthold, G. Alzen, L. Gortner, W. F. Blum, et al. Evidence for involvement of the vitamin D receptor gene in idiopathic short stature via a genome-wide linkage study and subsequent association studies Hum. Mol. Genet., September 15, 2006; 15(18): 2772 - 2783. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. d'Alesio, M. Garabedian, J. P. Sabatier, G. Guaydier-Souquieres, C. Marcelli, A. Lemacon, O. Walrant-Debray, and F. Jehan Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls Hum. Mol. Genet., November 15, 2005; 14(22): 3539 - 3548. [Abstract] [Full Text] [PDF] |
||||
![]() |
D-H Xiong, F-H Xu, P-Y Liu, H Shen, J-R Long, L Elze, R R Recker, and H-W Deng Vitamin D receptor gene polymorphisms are linked to and associated with adult height J. Med. Genet., March 1, 2005; 42(3): 228 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Poon, C. Laprise, M. Lemire, A. Montpetit, D. Sinnett, E. Schurr, and T. J. Hudson Association of Vitamin D Receptor Genetic Variants with Susceptibility to Asthma and Atopy Am. J. Respir. Crit. Care Med., November 1, 2004; 170(9): 967 - 973. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Chaves, D. Corella, J. V. Sorli, P. Marin-Garcia, M. Guillen, and J. Redon Polymorphisms of the Renin-Angiotensin System Influence Height in Normotensive Women in a Spanish Population J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2301 - 2305. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. E. Schuit, J. B. J. van Meurs, A. P. Bergink, M. van der Klift, Y. Fang, G. Leusink, A. Hofman, J. P. T. M. van Leeuwen, A. G. Uitterlinden, and H. A. P. Pols Height in Pre- and Postmenopausal Women Is Influenced by Estrogen Receptor {alpha} Gene Polymorphisms J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 303 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |